Arformoterol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Arformoterol
Arformoterol.svg
Arformoterol ball-and-stick model.png
Clinical data
Trade names Brovana
AHFS/Drugs.com Monograph
MedlinePlus a602023
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Inhalation solution for nebuliser
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
Protein binding 52–65%
Biological half-life 26 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
Formula C19H24N2O4
Molar mass 344.405 g/mol
 NYesY (what is this?)  (verify)

Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References[edit]

  1. ^ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14. 

External links[edit]